Next Article in Journal
A Novel Framework to Aid the Development of Design Space across Multi-Unit Operation Pharmaceutical Processes—A Case Study of Panax Notoginseng Saponins Immediate Release Tablet
Next Article in Special Issue
Formulation of Folate-Modified Raltitrexed-Loaded Nanoparticles for Colorectal Cancer Theranostics
Previous Article in Journal
Norovirus Capsid Protein-Derived Nanoparticles and Polymers as Versatile Platforms for Antigen Presentation and Vaccine Development
Previous Article in Special Issue
Ocular Biodistribution Studies Using Molecular Imaging
Review

A Role for Nanoparticles in Treating Traumatic Brain Injury

Department of Biological Systems Engineering, University of Nebraska-Lincoln, Lincoln, NE 68583-0726, USA
*
Author to whom correspondence should be addressed.
Pharmaceutics 2019, 11(9), 473; https://doi.org/10.3390/pharmaceutics11090473
Received: 12 August 2019 / Revised: 9 September 2019 / Accepted: 11 September 2019 / Published: 13 September 2019
(This article belongs to the Special Issue Molecular Imaging in Targeted Drug Delivery)
Traumatic brain injury (TBI) is one of the main causes of disability in children and young adults, as well as a significant concern for elderly individuals. Depending on the severity, TBI can have a long-term impact on the quality of life for survivors of all ages. The primary brain injury can result in severe disability or fatality, and secondary brain damage can increase the complexities in cellular, inflammatory, neurochemical, and metabolic changes in the brain, which can last decades post-injury. Thus, survival from a TBI is often accompanied by lifelong disabilities. Despite the significant morbidity, mortality, and economic loss, there are still no effective treatment options demonstrating an improved outcome in a large multi-center Phase III trial, which can be partially attributed to poor target engagement of delivered therapeutics. Thus, there is a significant unmet need to develop more effective delivery strategies to overcome the biological barriers that would otherwise inhibit transport of materials into the brain to prevent the secondary long-term damage associated with TBI. The complex pathology of TBI involving the blood-brain barrier (BBB) has limited the development of effective therapeutics and diagnostics. Therefore, it is of great importance to develop novel strategies to target the BBB. The leaky BBB caused by a TBI may provide opportunities for therapeutic delivery via nanoparticles (NP). The focus of this review is to provide a survey of NP-based strategies employed in preclinical models of TBI and to provide insights for improved NP based diagnostic or treatment approaches. Both passive and active delivery of various NPs for TBI are discussed. Finally, potential therapeutic targets where improved NP-mediated delivery could increase target engagement are identified with the overall goal of providing insight into open opportunities for NP researchers to begin research in TBI. View Full-Text
Keywords: TBI; blood-brain barrier; nanomedicine; neurotrauma; nanotheranostics TBI; blood-brain barrier; nanomedicine; neurotrauma; nanotheranostics
Show Figures

Graphical abstract

MDPI and ACS Style

Bony, B.A.; Kievit, F.M. A Role for Nanoparticles in Treating Traumatic Brain Injury. Pharmaceutics 2019, 11, 473. https://doi.org/10.3390/pharmaceutics11090473

AMA Style

Bony BA, Kievit FM. A Role for Nanoparticles in Treating Traumatic Brain Injury. Pharmaceutics. 2019; 11(9):473. https://doi.org/10.3390/pharmaceutics11090473

Chicago/Turabian Style

Bony, Badrul Alam; Kievit, Forrest M. 2019. "A Role for Nanoparticles in Treating Traumatic Brain Injury" Pharmaceutics 11, no. 9: 473. https://doi.org/10.3390/pharmaceutics11090473

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop